FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2515516401> ?p ?o ?g. }

• W2515516401 endingPage "3353" @default.
• W2515516401 startingPage "3344" @default.
• W2515516401 abstract "Antibodies inhibiting the programmed death receptor 1 (PD-1) have demonstrated significant activity in the treatment of advanced cutaneous melanoma. The efficacy and safety of PD-1 blockade in patients with uveal melanoma has not been well characterized.Fifty-eight patients with stage IV uveal melanoma received PD-1 or PD-1 ligand (PD-L1) antibodies between 2009 and 2015 at 9 academic centers. Patients who were evaluable for response were eligible for the analysis. Imaging was performed every 12 weeks and at the investigators' discretion. Safety and clinical efficacy outcomes, including the best overall response, progression-free survival (PFS), and overall survival (OS), were retrospectively determined.Of 56 eligible patients, 48 (86%) had received prior therapy, and 35 (63%) had received treatment with ipilimumab. Three patients had an objective response to ipilimumab, and 8 had stable disease as their best response. Thirty-eight patients (68%) received pembrolizumab, 16 (29%) received nivolumab, and 2 (4%) received atezolizumab. Objective tumor responses were observed in 2 patients for an overall response rate of 3.6% (95% confidence interval [CI], 1.8%-22.5%). Stable disease (≥6 months) was observed in 5 patients (9%). The median PFS was 2.6 months (95% CI, 2.4-2.8 months), and the median OS was 7.6 months (95% CI, 0.7-14.6 months). There was no association between prior treatment with ipilimumab or liver-directed therapy and PFS or OS. Treatment was well tolerated, and only 1 patient discontinued treatment because of toxicity.PD-1 and PD-L1 antibodies rarely confer durable remissions in patients with metastatic uveal melanoma. Clinical trial enrollment should be prioritized in this population. Cancer 2016;122:3344-3353. © 2016 American Cancer Society." @default.
• W2515516401 created "2016-09-16" @default.
• W2515516401 creator A5000401547 @default.
• W2515516401 creator A5008479799 @default.
• W2515516401 creator A5011325668 @default.
• W2515516401 creator A5018322482 @default.
• W2515516401 creator A5019869973 @default.
• W2515516401 creator A5025067315 @default.
• W2515516401 creator A5025872938 @default.
• W2515516401 creator A5035762857 @default.
• W2515516401 creator A5039301683 @default.
• W2515516401 creator A5040291209 @default.
• W2515516401 creator A5041066193 @default.
• W2515516401 creator A5072582710 @default.
• W2515516401 creator A5075566772 @default.
• W2515516401 creator A5086473468 @default.
• W2515516401 creator A5088042471 @default.
• W2515516401 creator A5091860403 @default.
• W2515516401 date "2016-08-17" @default.
• W2515516401 modified "2023-10-16" @default.
• W2515516401 title "Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies" @default.
• W2515516401 cites W1428284454 @default.
• W2515516401 cites W1508871122 @default.
• W2515516401 cites W1809627231 @default.
• W2515516401 cites W1940241680 @default.
• W2515516401 cites W1971208896 @default.
• W2515516401 cites W1982488143 @default.
• W2515516401 cites W2005576578 @default.
• W2515516401 cites W2013944616 @default.
• W2515516401 cites W2018032989 @default.
• W2515516401 cites W2019607817 @default.
• W2515516401 cites W2023916072 @default.
• W2515516401 cites W2038434969 @default.
• W2515516401 cites W2039123767 @default.
• W2515516401 cites W2053520756 @default.
• W2515516401 cites W2077517114 @default.
• W2515516401 cites W2097995306 @default.
• W2515516401 cites W2098835477 @default.
• W2515516401 cites W2104885590 @default.
• W2515516401 cites W2107429737 @default.
• W2515516401 cites W2110478149 @default.
• W2515516401 cites W2112121482 @default.
• W2515516401 cites W2118982164 @default.
• W2515516401 cites W2128035403 @default.
• W2515516401 cites W2152897456 @default.
• W2515516401 cites W2156353875 @default.
• W2515516401 cites W2160834915 @default.
• W2515516401 cites W2166662937 @default.
• W2515516401 cites W2166771927 @default.
• W2515516401 cites W2320786076 @default.
• W2515516401 cites W2508264364 @default.
• W2515516401 cites W2560367415 @default.
• W2515516401 cites W2572174216 @default.
• W2515516401 cites W2606964316 @default.
• W2515516401 cites W4293241248 @default.
• W2515516401 cites W634312238 @default.
• W2515516401 cites W2437909480 @default.
• W2515516401 doi "https://doi.org/10.1002/cncr.30258" @default.
• W2515516401 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5767160" @default.
• W2515516401 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27533448" @default.
• W2515516401 hasPublicationYear "2016" @default.
• W2515516401 type Work @default.
• W2515516401 sameAs 2515516401 @default.
• W2515516401 citedByCount "262" @default.
• W2515516401 countsByYear W25155164012016 @default.
• W2515516401 countsByYear W25155164012017 @default.
• W2515516401 countsByYear W25155164012018 @default.
• W2515516401 countsByYear W25155164012019 @default.
• W2515516401 countsByYear W25155164012020 @default.
• W2515516401 countsByYear W25155164012021 @default.
• W2515516401 countsByYear W25155164012022 @default.
• W2515516401 countsByYear W25155164012023 @default.
• W2515516401 crossrefType "journal-article" @default.
• W2515516401 hasAuthorship W2515516401A5000401547 @default.
• W2515516401 hasAuthorship W2515516401A5008479799 @default.
• W2515516401 hasAuthorship W2515516401A5011325668 @default.
• W2515516401 hasAuthorship W2515516401A5018322482 @default.
• W2515516401 hasAuthorship W2515516401A5019869973 @default.
• W2515516401 hasAuthorship W2515516401A5025067315 @default.
• W2515516401 hasAuthorship W2515516401A5025872938 @default.
• W2515516401 hasAuthorship W2515516401A5035762857 @default.
• W2515516401 hasAuthorship W2515516401A5039301683 @default.
• W2515516401 hasAuthorship W2515516401A5040291209 @default.
• W2515516401 hasAuthorship W2515516401A5041066193 @default.
• W2515516401 hasAuthorship W2515516401A5072582710 @default.
• W2515516401 hasAuthorship W2515516401A5075566772 @default.
• W2515516401 hasAuthorship W2515516401A5086473468 @default.
• W2515516401 hasAuthorship W2515516401A5088042471 @default.
• W2515516401 hasAuthorship W2515516401A5091860403 @default.
• W2515516401 hasBestOaLocation W25155164012 @default.
• W2515516401 hasConcept C121608353 @default.
• W2515516401 hasConcept C126322002 @default.
• W2515516401 hasConcept C141071460 @default.
• W2515516401 hasConcept C143998085 @default.
• W2515516401 hasConcept C2775949291 @default.
• W2515516401 hasConcept C2777658100 @default.
• W2515516401 hasConcept C2777701055 @default.
• W2515516401 hasConcept C2780030458 @default.

• next